265 related articles for article (PubMed ID: 24063900)
1. [Telaprevir resistance].
Poveda E; García F
Enferm Infecc Microbiol Clin; 2013 Jul; 31 Suppl 3():26-32. PubMed ID: 24063900
[TBL] [Abstract][Full Text] [Related]
2. In vitro phenotypic characterization of hepatitis C virus NS3 protease variants observed in clinical studies of telaprevir.
Jiang M; Mani N; Lin C; Ardzinski A; Nelson M; Reagan D; Bartels D; Zhou Y; Nicolas O; Rao BG; Müh U; Hanzelka B; Tigges A; Rijnbrand R; Kieffer TL
Antimicrob Agents Chemother; 2013 Dec; 57(12):6236-45. PubMed ID: 24100495
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis C viral evolution in genotype 1 treatment-naïve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials.
Kieffer TL; De Meyer S; Bartels DJ; Sullivan JC; Zhang EZ; Tigges A; Dierynck I; Spanks J; Dorrian J; Jiang M; Adiwijaya B; Ghys A; Beumont M; Kauffman RS; Adda N; Jacobson IM; Sherman KE; Zeuzem S; Kwong AD; Picchio G
PLoS One; 2012; 7(4):e34372. PubMed ID: 22511937
[TBL] [Abstract][Full Text] [Related]
4. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir.
Sarrazin C; Kieffer TL; Bartels D; Hanzelka B; Müh U; Welker M; Wincheringer D; Zhou Y; Chu HM; Lin C; Weegink C; Reesink H; Zeuzem S; Kwong AD
Gastroenterology; 2007 May; 132(5):1767-77. PubMed ID: 17484874
[TBL] [Abstract][Full Text] [Related]
5. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients.
Kieffer TL; Sarrazin C; Miller JS; Welker MW; Forestier N; Reesink HW; Kwong AD; Zeuzem S
Hepatology; 2007 Sep; 46(3):631-9. PubMed ID: 17680654
[TBL] [Abstract][Full Text] [Related]
6. Characterization of telaprevir treatment outcomes and resistance in patients with prior treatment failure: results from the REALIZE trial.
De Meyer S; Dierynck I; Ghys A; Beumont M; Daems B; Van Baelen B; Sullivan JC; Bartels DJ; Kieffer TL; Zeuzem S; Picchio G
Hepatology; 2012 Dec; 56(6):2106-15. PubMed ID: 22806681
[TBL] [Abstract][Full Text] [Related]
7. Analysis of genotype 2 and 3 hepatitis C virus variants in patients treated with telaprevir demonstrates a consistent resistance profile across genotypes.
De Meyer S; Ghys A; Foster GR; Beumont M; Van Baelen B; Lin TI; Dierynck I; Ceulemans H; Picchio G
J Viral Hepat; 2013 Jun; 20(6):395-403. PubMed ID: 23647956
[TBL] [Abstract][Full Text] [Related]
8. [Determination of drug resistance mutations of NS3 inhibitors in chronic hepatitis C patients infected with genotype 1].
Şanlıdağ T; Sayan M; Akçalı S; Kasap E; Buran T; Arıkan A
Mikrobiyol Bul; 2017 Apr; 51(2):145-155. PubMed ID: 28566078
[TBL] [Abstract][Full Text] [Related]
9. [Biochemical and pharmacological features of telaprevir].
Andrade RJ; García-Samaniego J
Enferm Infecc Microbiol Clin; 2013 Jul; 31 Suppl 3():2-6. PubMed ID: 24063896
[TBL] [Abstract][Full Text] [Related]
10. Naturally Occurring Resistance-Associated Variants of Hepatitis C Virus Protease Inhibitors in Poor Responders to Pegylated Interferon-Ribavirin.
Larrat S; Vallet S; David-Tchouda S; Caporossi A; Margier J; Ramière C; Scholtes C; Haïm-Boukobza S; Roque-Afonso AM; Besse B; André-Garnier E; Mohamed S; Halfon P; Pivert A; LeGuillou-Guillemette H; Abravanel F; Guivarch M; Mackiewicz V; Lada O; Mourez T; Plantier JC; Baazia Y; Alain S; Hantz S; Thibault V; Gaudy-Graffin C; Bouvet D; Mirand A; Henquell C; Gozlan J; Lagathu G; Pronier C; Velay A; Schvoerer E; Trimoulet P; Fleury H; Bouvier-Alias M; Brochot E; Duverlie G; Maylin S; Gouriou S; Pawlotsky JM; Morand P
J Clin Microbiol; 2015 Jul; 53(7):2195-202. PubMed ID: 25926499
[TBL] [Abstract][Full Text] [Related]
11. GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796.
McCown MF; Rajyaguru S; Kular S; Cammack N; Nájera I
Antimicrob Agents Chemother; 2009 May; 53(5):2129-32. PubMed ID: 19273674
[TBL] [Abstract][Full Text] [Related]
12. Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir.
Hofmann WP; Chung TL; Osbahr C; Susser S; Karey U; Mihm U; Welsch C; Lötsch J; Sarrazin C; Zeuzem S; Herrmann E
Antivir Ther; 2011; 16(5):695-704. PubMed ID: 21817191
[TBL] [Abstract][Full Text] [Related]
13. Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice.
Cento V; Tontodonati M; Di Maio VC; Bellocchi MC; Valenti F; Manunta A; Fortuna S; Armenia D; Carioti L; Antonucci FP; Bertoli A; Trave F; Cacciatore P; Angelico M; Navarra P; Neumann AU; Vecchiet J; Parruti G; Babudieri S; Perno CF; Ceccherini-Silberstein F
Dig Liver Dis; 2015 Mar; 47(3):233-41. PubMed ID: 25637450
[TBL] [Abstract][Full Text] [Related]
14. [Significance of hepatitis C virus baseline polymorphism during the antiviral therapy].
Tornai I
Orv Hetil; 2015 May; 156(21):849-54. PubMed ID: 26038992
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis C virus resistance to protease inhibitors.
Halfon P; Locarnini S
J Hepatol; 2011 Jul; 55(1):192-206. PubMed ID: 21284949
[TBL] [Abstract][Full Text] [Related]
16. Nationwide experience of treatment with protease inhibitors in chronic hepatitis C patients in Denmark: identification of viral resistance mutations.
Sølund C; Krarup H; Ramirez S; Thielsen P; Røge BT; Lunding S; Barfod TS; Madsen LG; Tarp B; Christensen PB; Gerstoft J; Laursen AL; Bukh J; Weis N;
PLoS One; 2014; 9(12):e113034. PubMed ID: 25438153
[TBL] [Abstract][Full Text] [Related]
17. Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France.
Aherfi S; Solas C; Motte A; Moreau J; Borentain P; Mokhtari S; Botta-Fridlund D; Dhiver C; Portal I; Ruiz JM; Ravaux I; Bregigeon S; Poizot-Martin I; Stein A; Gérolami R; Brouqui P; Tamalet C; Colson P
J Med Virol; 2014 Nov; 86(11):1868-76. PubMed ID: 25052594
[TBL] [Abstract][Full Text] [Related]
18. Rapid emergence of telaprevir resistant hepatitis C virus strain from wildtype clone in vivo.
Hiraga N; Imamura M; Abe H; Hayes CN; Kono T; Onishi M; Tsuge M; Takahashi S; Ochi H; Iwao E; Kamiya N; Yamada I; Tateno C; Yoshizato K; Matsui H; Kanai A; Inaba T; Tanaka S; Chayama K
Hepatology; 2011 Sep; 54(3):781-8. PubMed ID: 21626527
[TBL] [Abstract][Full Text] [Related]
19. Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease.
Zhou Y; Bartels DJ; Hanzelka BL; Müh U; Wei Y; Chu HM; Tigges AM; Brennan DL; Rao BG; Swenson L; Kwong AD; Lin C
Antimicrob Agents Chemother; 2008 Jan; 52(1):110-20. PubMed ID: 17938182
[TBL] [Abstract][Full Text] [Related]
20. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients.
Kuntzen T; Timm J; Berical A; Lennon N; Berlin AM; Young SK; Lee B; Heckerman D; Carlson J; Reyor LL; Kleyman M; McMahon CM; Birch C; Schulze Zur Wiesch J; Ledlie T; Koehrsen M; Kodira C; Roberts AD; Lauer GM; Rosen HR; Bihl F; Cerny A; Spengler U; Liu Z; Kim AY; Xing Y; Schneidewind A; Madey MA; Fleckenstein JF; Park VM; Galagan JE; Nusbaum C; Walker BD; Lake-Bakaar GV; Daar ES; Jacobson IM; Gomperts ED; Edlin BR; Donfield SM; Chung RT; Talal AH; Marion T; Birren BW; Henn MR; Allen TM
Hepatology; 2008 Dec; 48(6):1769-78. PubMed ID: 19026009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
